TLDR These new skin treatments are safer and more effective with minimal side effects.
This review evaluates the pharmacokinetics, pharmacodynamics, and systemic absorption of five novel topical dermatologic agents: ruxolitinib cream, tirbanibulin ointment, clascoterone cream, minocycline foam, and tapinarof cream. These agents, used for conditions like acne and atopic dermatitis, show low plasma concentrations and bioavailability, indicating minimal systemic absorption and a low risk of adverse effects. They represent a significant advancement in dermatologic care by improving safety, tolerability, and efficacy compared to traditional treatments. However, further research is needed to assess their long-term safety and efficacy.
5 citations
,
January 2024 in “Journal of the American Academy of Dermatology” Use benzoyl peroxide, retinoids, antibiotics, and isotretinoin for acne, and combine treatments for better results.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
27 citations
,
October 2020 in “Drugs” Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
September 2022 in “Dermatology and therapy” Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.
1 citations
,
July 2018 in “Elsevier eBooks” Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
July 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
